Compare ACEL & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | MRVI |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2017 | 2020 |
| Metric | ACEL | MRVI |
|---|---|---|
| Price | $12.01 | $6.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $14.67 | $4.13 |
| AVG Volume (30 Days) | 241.1K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.34 | 14.29 |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $7.07 | $12.54 |
| Revenue Next Year | $2.81 | $7.87 |
| P/E Ratio | $70.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.55 | $1.99 |
| 52 Week High | $14.00 | $7.44 |
| Indicator | ACEL | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 52.89 |
| Support Level | $11.71 | $3.36 |
| Resistance Level | $13.29 | $6.55 |
| Average True Range (ATR) | 0.31 | 0.37 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 11.81 | 17.12 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.